Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag

2015 ◽  
Vol 87 (12) ◽  
pp. 2090-2097 ◽  
Author(s):  
Wei Sun ◽  
Qun Li ◽  
Dandan Zhu ◽  
Jinrong Feng ◽  
Zhong Zhuang ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Dna Vaccine ◽  
Fusion Tag

scholarly journals Modulation of the Immune Response Induced by Gene Electrotransfer of a Hepatitis C Virus DNA Vaccine in Nonhuman Primates

2006 ◽  
Vol 177 (10) ◽  
pp. 7462-7471 ◽  
Author(s):  
Stefania Capone ◽  
Immacolata Zampaglione ◽  
Alessandra Vitelli ◽  
Monica Pezzanera ◽  
Lisa Kierstead ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Dna Vaccine ◽  
Nonhuman Primates ◽  
Gene Electrotransfer

scholarly journals Hepatitis C Virus Reveals a Novel Early Control in Acute Immune Response

2011 ◽  
Vol 7 (10) ◽  
pp. e1002289 ◽  
Author(s):  
Noëlla Arnaud ◽  
Stéphanie Dabo ◽  
Daisuke Akazawa ◽  
Masayoshi Fukasawa ◽  
Fumiko Shinkai-Ouchi ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C

Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study

2021 ◽  
Author(s):  
Haidi Karam-Allah Ramadan ◽  
Gamal Badr ◽  
Nancy K Ramadan ◽  
Aml Sayed
Keyword(s):  
Immune Response ◽  
Liver Cirrhosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Immune Responses ◽  
Signaling Pathways ◽  
Liver Diseases ◽  
Stat Signaling ◽  
Chronic Hcv ◽  
Direct Acting

Abstract The use of direct-acting antivirals (DAAs) therapy for the treatment of hepatitis C virus (HCV) results in a high sustained virological response (SVR) and subsequently alters liver immunologic environment. However, hepatocellular carcinoma (HCC) may occur after DAAs treatment. We aimed to clarify changes of immune responses, PI3K/AKT and JAK/STAT signaling pathways in HCV-induced liver diseases and HCC following DAAs treatment. Four cohorts are classified as chronic HCV patients, HCV-related cirrhosis without HCC, HCV-related cirrhosis and HCC, and healthy control group. The patient groups were further divided into treated or untreated with DAAs with SVR12. Increased percentages of CD3, CD8 and CD4, decreased CD4/FoxP3/CD25, CD8/PD-1 and CD19/PDL-1 were found in DAAs-treated patients in the three HCV groups. Following DAAs therapy, the levels of ROS, IL-1β, IL-6, IL-8 and TNF-α were significantly decreased in the three HCV groups. Treated HCV patients showed up regulation of p-AKT and p-STAT5 and down regulation of p-STAT3, HIF-1α and COX-2. In conclusion, DAAs enhance the immune response in chronic HCV and liver cirrhosis, hence our study is the first to show change in PI3K/AKT and JAK/STAT signaling pathways in different HCV-induced liver diseases after DAAs. In chronic HCV, DAAs have better impact on the immune response while in liver cirrhosis not all immune changes were prominent.

scholarly journals Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments

Hepatology ◽  
1998 ◽  
Vol 28 (3) ◽  
pp. 810-814 ◽  
Author(s):  
Roberto Burioni ◽  
Paola Plaisant ◽  
Aldo Manzin ◽  
Domenico Rosa ◽  
Valeria Delli Carri ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Humoral Immune Response ◽  
Humoral Immune ◽  
Fab Fragments ◽  
E2 Glycoprotein
Sign in / Sign up

Export Citation Format

Share Document